文献速递急性肾损伤慢性肾脏病

美国国立卫生研究院研讨会:优化肾脏精准医学临床试验以加速治疗创新

National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-02-17

美国国立糖尿病、消化和肾脏疾病研究所于2024年举办「为肾脏精准医学临床试验做准备」科学研讨会,旨在理解肾病患者治疗历程并确定精准医学策略、靶点和试验准备度的候选指标。与会者识别肾脏精准医学临床试验的最佳实践、机遇和障碍,以优化试验设计与实施,患者视角为会议基础。

要点

  • 临床试验设计应灵活、动态、响应患者照护转变并减少照护碎片化。
  • 理解机制、定义内表型和靶点可促进急性和慢性肾病的新治疗策略。
  • 生物标志物对诊断和评估治疗反应至关重要,实验室网络支持的大型精准试验提供范例。

核心结论

  • 优化临床试验设计需考虑遗传差异和疾病机制状态,以验证以个体患者为中心的创新有效精准治疗方法。

研究设计与样本

  • 美国国立糖尿病、消化和肾脏疾病研究所于2024年赞助的科学研讨会,参与者包括多学科专家,以患者视角为基础。

主要发现

  • 试验设计应灵活、动态、响应患者照护转变并减少照护碎片化。
  • 理解机制、定义内表型和靶点可促进急性和慢性肾病新治疗策略。
  • 生物标志物对诊断和评估治疗反应至关重要。
  • 肾脏精准试验障碍包括患者参与、专业知识、基础设施和财务资源不足。

临床怎么用

  • 采用灵活动态的试验设计,响应患者照护转变并减少碎片化。
  • 利用机制理解、内表型和靶点开发新治疗策略。
  • 应用生物标志物进行诊断和评估治疗反应。
  • 通过示范项目测试各种方法以加速将正确治疗给予正确患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The National Institute of Diabetes and Digestive and Kidney Diseases sponsored a scientific workshop in 2024, titled "Preparing for Kidney Precision Medicine Clinical Trials." The purpose of the workshop was to gain a better understanding of the therapeutic journey of patients with kidney disease and define candidate indicators for precision medicine strategies, targets, and trial readiness. Workshop participants were tasked with identifying best practices, opportunities, and barriers to kidney precision medicine clinical trials, with a shared goal to optimize the design and conduct of these trials. The patient perspective served as a foundation for the meeting. Trial design should be flexible, dynamic, responsive to transitions in patient care and minimize fragmentation of care. The value of understanding mechanisms and defining endophenotypes and targets to facilitate new therapeutic approaches was discussed with examples presented for acute and CKDs. The importance of biomarkers for diagnosis and evaluation of therapeutic response was emphasized. Laboratory and assay considerations for precision medicine trials were discussed with examples of successful large precision medicine trials supported by laboratory networks presented. There was discussion of the barriers to precision trials in nephrology, including suboptimal patient engagement, precision trial expertise, infrastructure, and financial resources. Engagement in demonstration projects to test the ability of various approaches to expedite the right treatment to the right patient was highlighted. Of utmost importance is the better design of clinical trials which consider differences in genetics and status of disease mechanisms to validate individual patient-focused innovative and effective precision therapeutic approaches.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Joy MS, Gbadegesin RA, Conway PT, et al. National Institutes of Health Workshop to Accelerate Therapeutic Innovation by Optimizing Kidney Precision Medicine Clinical Trials. Clin J Am Soc Nephrol. 2026. PMID: 41701531. doi:10.2215/CJN.0000001031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。